Background
Methods
Study design and data source
Source and study populations
Febrile neutropenia
Statistical analyses
Results
Patient characteristics
Commercial | Medicare | |||
---|---|---|---|---|
No Pegfilgrastim Use | Pegfilgrastim Use | No Pegfilgrastim Use | Pegfilgrastim Use | |
(n = 16,512) | (n = 34,266) | (n = 20,195) | (n = 50,842) | |
Patient | ||||
Age (years) | ||||
Mean (SD) | 54.3 (10.2) | 56.2 (10.9) | 72.3 (5.4) | 73.6 (5.9) |
Female, N (%) | 14,623 (89%) | 29,995 (88%) | 16,604 (82%) | 37,811 (74%) |
Chronic Comorbidities, N (%) | ||||
Cardiovascular Disease | 1403 (8%) | 3851 (11%) | 6124 (30%) | 16,979 (33%) |
Diabetes | 1750 (11%) | 4211 (12%) | 5217 (26%) | 13,022 (26%) |
Liver Disease | 621 (4%) | 1386 (4%) | 731 (4%) | 1999 (4%) |
Lung Disease | 1290 (8%) | 3157 (9%) | 3033 (15%) | 8053 (16%) |
Renal Disease | 311 (2%) | 855 (2%) | 1523 (8%) | 4598 (9%) |
Osteoarthritis | 1382 (8%) | 3361 (10%) | 4534 (22%) | 11,620 (23%) |
Rheumatoid Disease | 236 (1%) | 561 (2%) | 670 (3%) | 1798 (4%) |
Thyroid Disorder | 2105 (13%) | 4569 (13%) | 4470 (22%) | 11,723 (23%) |
Body Weight and Nutritional Status, N (%) | ||||
Obese | 1244 (8%) | 2688 (8%) | 1715 (8%) | 3959 (8%) |
Malnutrition | 71 (0%) | 289 (1%) | 414 (2%) | 1517 (3%) |
Proxies for Health Status, N (%) | ||||
Hospice Care | 38 (0%) | 120 (0%) | 572 (3%) | 2037 (4%) |
SNF | 100 (1%) | 244 (1%) | 926 (5%) | 2194 (4%) |
Hospice or SNF | 136 (1%) | 352 (1%) | 1400 (7%) | 3962 (8%) |
Proxies for Physical Function, N (%) | ||||
Use of Hospital Bed | 26 (0%) | 78 (0%) | 162 (1%) | 476 (1%) |
Use of Supplemental Oxygen | 259 (2%) | 681 (2%) | 810 (4%) | 2285 (4%) |
Use of Walking Aid | 192 (1%) | 506 (1%) | 772 (4%) | 2455 (5%) |
Use of Wheel Chair | 53 (0%) | 136 (0%) | 378 (2%) | 997 (2%) |
Any of Above | 487 (3%) | 1256 (4%) | 1807 (9%) | 5268 (10%) |
Use of Immunosuppressive Drugs, N (%) | 5273 (32%) | 11,113 (32%) | 6612 (33%) | 17,145 (34%) |
Other Conditions/Events Prior to Chemotherapy, N (%) | ||||
Anemia | 1896 (11%) | 4721 (14%) | 6025 (30%) | 17,970 (35%) |
Neutropenia | 290 (2%) | 1295 (4%) | 948 (5%) | 4738 (9%) |
Infection | 7902 (48%) | 17,204 (50%) | 11,545 (57%) | 29,868 (59%) |
Recent Surgery (prior 90 days) | 13,881 (84%) | 28,100 (82%) | 13,024 (64%) | 30,427 (60%) |
History of Hospitalization for Any Reason | 4549 (28%) | 9985 (29%) | 7739 (38%) | 20,374 (40%) |
History of Chemotherapy | 866 (5%) | 2127 (6%) | 1623 (8%) | 4755 (9%) |
History of Radiation Therapy | 910 (6%) | 1955 (6%) | 883 (4%) | 2140 (4%) |
Cancer and Chemotherapy, N (%) | ||||
Breast Cancer | 13,261 (80%) | 26,622 (78%) | 13,305 (66%) | 25,675 (50%) |
TAC | 389 (2%) | 4179 (12%) | 235 (1%) | 1857 (4%) |
TC | 8793 (53%) | 14,918 (44%) | 8032 (40%) | 19,493 (38%) |
TCH | 4079 (25%) | 7525 (22%) | 5038 (25%) | 4325 (9%) |
NHL — CHOP±R | 3251 (20%) | 7644 (22%) | 6890 (34%) | 25,167 (50%) |
Year of Chemotherapy (Commercial), N (%) | ||||
2010–2011 | 7150 (43%) | 13,308 (39%) | – | – |
2012–2013 | 6108 (37%) | 13,108 (38%) | – | – |
2014–2015 | 3254 (20%) | 7850 (23%) | – | – |
Year of Chemotherapy (Medicare), N (%) | ||||
2007–2009 | – | – | 6268 (31%) | 12,984 (26%) |
2010–2012 | – | – | 8615 (43%) | 21,004 (41%) |
2013–2015 | – | – | 5312 (26%) | 16,854 (33%) |
Patterns of Pegfilgrastim prophylaxis and crude FN risk
Commercial | Medicare | |||||||
---|---|---|---|---|---|---|---|---|
Pegfilgrastim Use | Pegfilgrastim Use | |||||||
No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | |
Cycle 1 | ||||||||
FN Events Prior to Cycle 1 | ||||||||
No | 50,778 (100%) | 16,512 (33%) | 34,266 (67%) | – | 71,037 (100%) | 20,195 (28%) | 50,842 (72%) | – |
Yes | – | – | – | – | – | – | – | – |
Cycle 2 | 41,769 | 11,719 (28%) | 30,050 (72%) | 59,412 | 15,193 (26%) | 44,219 (74%) | ||
FN Events Prior to Cycle 2 | ||||||||
No | 40,123 (96%) | 11,482 (29%) | 28,641 (71%) | – | 55,488 (93%) | 14,483 (26%) | 41,005 (74%) | – |
Yes | 1646 (4%) | 237 (14%) | 1409 (86%) | 2.4 (2.1–2.7) | 3924 (7%) | 710 (18%) | 3214 (82%) | 1.6 (1.5–1.7) |
Cycles ≥3 | 98,075 | 24,834 (25%) | 73,241 (75%) | 141,495 | 43,012 (30%) | 98,483 (70%) | ||
FN Events Prior to Cycle of Interest | ||||||||
No | 91,744 (94%) | 23,875 (26%) | 67,869 (74%) | – | 126,424 (89%) | 39,360 (31%) | 87,064 (69%) | – |
Yes | 6331 (6%) | 959 (15%) | 5372 (85%) | 2.0 (1.8–2.1) | 15,071 (11%) | 3652 (24%) | 11,419 (76%) | 1.4 (1.4–1.5) |
Last Cycle | 34,860 | 10,188 (29%) | 24,672 (71%) | 51,989 | 20,099 (39%) | 31,890 (61%) | ||
FN Events Prior to Last Cycle | ||||||||
No | 32,541 (93%) | 9774 (30%) | 22,767 (70%) | – | 46,115 (89%) | 18,215 (39%) | 27,900 (61%) | – |
Yes | 2319 (7%) | 414 (18%) | 1905 (82%) | 2.0 (1.8–2.2) | 5874 (11%) | 1884 (32%) | 3990 (68%) | 1.4 (1.3–1.5) |
All Cycles | 190,622 | 53,065 (28%) | 137,557 (72%) | 271,944 | 78,400 (29%) | 193,544 (71%) | ||
FN Events Prior to Cycle of Interest | ||||||||
No | 182,645 (96%) | 51,869 (28%) | 130,776 (72%) | – | 252,949 (93%) | 74,038 (29%) | 178,911 (71%) | – |
Yes | 7977 (4%) | 1196 (15%) | 6781 (85%) | 2.2 (2.1–2.4) | 18,995 (7%) | 4362 (23%) | 14,633 (77%) | 1.4 (1.3–1.4) |
Commercial | Medicare | |||||||
---|---|---|---|---|---|---|---|---|
FN in Cycle | FN in Cycle | |||||||
No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | |
Cycle 1 | 50,778 | 48,157 (95%) | 2621 (5%) | 71,037 | 64,249 (90%) | 6788 (10%) | ||
Use of Pegfilgrastim Prophylaxis | ||||||||
No | 16,512 (33%) | 15,234 (92%) | 1278 (8%) | – | 20,195 (28%) | 17,901 (89%) | 2294 (11%) | – |
Yes | 34,266 (67%) | 32,923 (96%) | 1343 (4%) | 2.1 (1.9–2.2) | 50,842 (72%) | 46,348 (91%) | 4494 (9%) | 1.3 (1.3–1.4) |
Cycle 2 | 41,769 | 40,810 (98%) | 959 (2%) | 59,412 | 56,343 (95%) | 3069 (5%) | ||
Use of Pegfilgrastim Prophylaxis | ||||||||
No | 11,719 (28%) | 11,353 (97%) | 366 (3%) | – | 15,193 (26%) | 14,282 (94%) | 911 (6%) | – |
Yes | 30,050 (72%) | 29,457 (98%) | 593 (2%) | 1.6 (1.4–1.8) | 44,219 (74%) | 42,061 (95%) | 2158 (5%) | 1.2 (1.1–1.3) |
Cycles ≥3 | 98,075 | 96,006 (98%) | 2069 (2%) | 141,495 | 134,363 (95%) | 7132 (5%) | ||
Use of Pegfilgrastim Prophylaxis | ||||||||
No | 24,834 (25%) | 24,229 (98%) | 605 (2%) | – | 43,012 (30%) | 40,842 (95%) | 2170 (5%) | – |
Yes | 73,241 (75%) | 71,777 (98%) | 1464 (2%) | 1.2 (1.1–1.3) | 98,483 (70%) | 93,521 (95%) | 4962 (5%) | 1.0 (1.0–1.1) |
Last Cycle | 34,860 | 33,426 (96%) | 1434 (4%) | 51,989 | 45,392 (87%) | 6597 (13%) | ||
Use of Pegfilgrastim Prophylaxis | ||||||||
No | 10,188 (29%) | 9705 (95%) | 483 (5%) | – | 20,099 (39%) | 17,851 (89%) | 2248 (11%) | – |
Yes | 24,672 (71%) | 23,721 (96%) | 951 (4%) | 1.2 (1.1–1.4) | 31,890 (61%) | 27,541 (86%) | 4349 (14%) | 0.8 (0.8–0.8) |
All Cycles | 190,622 | 184,973 (97%) | 5649 (3%) | 271,944 | 254,955 (94%) | 16,989 (6%) | ||
Use of Pegfilgrastim Prophylaxis | ||||||||
No | 53,065 (28%) | 50,816 (96%) | 2249 (4%) | – | 78,400 (29%) | 73,025 (93%) | 5375 (7%) | – |
Yes | 137,557 (72%) | 134,157 (98%) | 3400 (2%) | 1.7 (1.7–1.8) | 193,544 (71%) | 181,930 (94%) | 11,614 (6%) | 1.2 (1.1–1.2) |
Multivariable analysis of FN
Adjusted Odds Ratio for FN (95% CI, p-value)* | |||||
---|---|---|---|---|---|
Cycle 1 | Cycle 2 | Cycles ≥3 | Last Cycle | All Cycles | |
Commercial | |||||
Independent Variables | |||||
No PEG Prophylaxis | 2.6 (2.3–2.8, < 0.001) | 1.9 (1.6–2.2, < 0.001) | 1.5 (1.4–1.7, < 0.001) | 1.5 (1.4–1.7, < 0.001) | 2.1 (2.0–2.3, < 0.001) |
FN in Prior Cycle | – | 3.2 (2.6–3.9, < 0.001) | 3.5 (3.2–4.0, < 0.001) | 2.4 (2.0–2.8, < 0.001) | 2.4 (2.2–2.6, < 0.001) |
Regimen | |||||
TAC | 2.9 (2.6–3.3, < 0.001) | 2.6 (1.7–4.1, < 0.001) | 1.7 (1.4–1.9, < 0.001) | 3.3 (2.4–4.8, < 0.001) | 2.7 (2.2–3.2, < 0.001) |
TC | – | – | – | – | – |
TCH | 1.1 (1.0–1.2, 0.229) | 2.2 (1.4–3.3, < 0.001) | 1.1 (1.0–1.2, 0.266) | 2.1 (1.5–2.9, < 0.001) | 1.4 (1.2–1.6, < 0.001) |
CHOP±R | 1.3 (1.2–1.5, < 0.001) | 4.1 (1.9–9.0, < 0.001) | 1.7 (1.5–1.9, < 0.001) | 4.3 (2.4–7.7, < 0.001) | 2.6 (1.9–3.5, < 0.001) |
Age | |||||
18–49 | – | – | – | – | – |
50–64 | 1.0 (0.9–1.1, 0.377) | 1.0 (0.9–1.2, 0.884) | 1.1 (1.0–1.2, 0.242) | 1.3 (1.1–1.4, 0.002) | 1.0 (1.0–1.1, 0.409) |
65–74 | 1.3 (1.2–1.5, < 0.001) | 1.0 (0.8–1.2, 0.881) | 1.5 (1.3–1.8, < 0.001) | 1.7 (1.4–2.1, < 0.001) | 1.3 (1.2–1.4, < 0.001) |
≥ 75 | 1.7 (1.4–2.1, < 0.001) | 1.2 (0.9–1.7, 0.200) | 2.1 (1.8–2.6, < 0.001) | 3.4 (2.7–4.3, < 0.001) | 1.7 (1.5–2.0, < 0.001) |
Medicare | |||||
Independent Variables | |||||
No PEG Prophylaxis | 1.6 (1.5–1.7, < 0.001) | 1.6 (1.5–1.8, < 0.001) | 1.3 (1.3–1.4, < 0.001) | 1.0 (0.9–1.0, 0.507) | 1.5 (1.4–1.5, < 0.001) |
FN in Prior Cycle | – | 3.2 (2.9–3.5, < 0.001) | 2.9 (2.7–3.1, < 0.001) | 1.7 (1.6–1.8, < 0.001) | 2.1 (2.1–2.2, < 0.001) |
Regimen | |||||
TAC | 2.5 (2.2–2.9, < 0.001) | 1.9 (1.5–2.4, < 0.001) | 2.0 (1.7–2.3, < 0.001) | 2.2 (1.9–2.6, < 0.001) | 2.1 (1.9–2.3, < 0.001) |
TC | – | – | – | – | – |
TCH | 0.8 (0.7–0.9, < 0.001) | 0.9 (0.8–1.0, 0.127) | 0.8 (0.7–0.9, < 0.001) | 1.0 (0.9–1.2, 0.387) | 0.8 (0.7–0.8, < 0.001) |
CHOP±R | 1.5 (1.4–1.5, < 0.001) | 1.8 (1.7–2.0, < 0.001) | 1.9 (1.8–2.0, < 0.001) | 1.8 (1.7–2.0, < 0.001) | 1.6 (1.6–1.7, < 0.001) |
Age | |||||
65–74 | – | – | – | – | – |
75–84 | 1.2 (1.1–1.3, < 0.001) | 1.0 (0.9–1.1, 0.709) | 1.1 (1.1–1.2, < 0.001) | 1.2 (1.1–1.3, < 0.001) | 1.1 (1.1–1.2, < 0.001) |
≥ 85 | 1.4 (1.3–1.5, < 0.001) | 1.2 (1.1–1.4, < 0.001) | 1.4 (1.3–1.5, < 0.001) | 1.8 (1.6–1.9, < 0.001) | 1.4 (1.3–1.4, < 0.001) |
Adjusted Odds Ratio for FN (95% CI, p-value)* | |||||
---|---|---|---|---|---|
Cycle 1 | Cycle 2 | Cycles ≥3 | Last Cycle | All Cycles | |
Commercial | |||||
Independent Variables | |||||
No PEG Prophylaxis | 4.2 (3.8–4.7, < 0.001) | 4.1 (3.3–4.9, < 0.001) | 3.3 (2.9–3.8, < 0.001) | 3.2 (2.7–3.8, < 0.001) | 4.2 (3.9–4.5, < 0.001) |
FN in Prior Cycle | – | 5.1 (3.7–7.0, < 0.001) | 5.9 (4.9–7.0, < 0.001) | 3.9 (3.0–5.0, < 0.001) | 3.1 (2.6–3.5, < 0.001) |
Regimen | |||||
TAC | 4.4 (3.8–5.1, < 0.001) | 2.2 (1.6–3.2, < 0.001) | 3.0 (2.4–3.8, < 0.001) | 2.7 (2.0–3.6, < 0.001) | 4.1 (3.3–5.2, < 0.001) |
TC | – | – | – | – | – |
TCH | 1.0 (0.9–1.1, 0.963) | 1.4 (1.1–1.8, 0.009) | 1.2 (1.0–1.4, 0.130) | 1.2 (0.9–1.5, 0.191) | 1.3 (1.0–1.6, 0.040) |
CHOP±R | 1.4 (1.2–1.6, < 0.001) | 2.0 (1.5–2.7, < 0.001) | 3.5 (2.9–4.4, < 0.001) | 1.7 (1.4–2.1, < 0.001) | 3.0 (2.0–4.5, < 0.001) |
Age | |||||
18–49 | – | – | – | – | – |
50–64 | 1.1 (1.0–1.2, 0.216) | 1.1 (0.9–1.4, 0.332) | 1.0 (0.9–1.2, 0.671) | 1.3 (1.1–1.6, 0.010) | 1.1 (1.0–1.2, 0.207) |
65–74 | 1.5 (1.3–1.8, < 0.001) | 1.2 (0.8–1.6, 0.354) | 1.4 (1.1–1.8, 0.002) | 1.6 (1.2–2.1, 0.003) | 1.4 (1.3–1.6, < 0.001) |
≥ 75 | 2.1 (1.7–2.7, < 0.001) | 1.7 (1.1–2.6, 0.012) | 2.0 (1.5–2.6, < 0.001) | 4.0 (2.9–5.5, < 0.001) | 2.1 (1.7–2.4, < 0.001) |
Medicare | |||||
Independent Variables | |||||
No PEG Prophylaxis | 2.0 (1.9–2.2, < 0.001) | 2.2 (2.0–2.5, < 0.001) | 1.6 (1.5–1.8, < 0.001) | 1.3 (1.2–1.4, < 0.001) | 1.9 (1.8–2.0, < 0.001) |
FN in Prior Cycle | – | 4.6 (4.0–5.3, < 0.001) | 4.1 (3.8–4.4, < 0.001) | 2.4 (2.1–2.6, < 0.001) | 2.7 (2.5–2.9, < 0.001) |
Regimen | |||||
TAC | 3.1 (2.7–3.7, < 0.001) | 2.5 (1.9–3.5, < 0.001) | 2.8 (2.3–3.5, < 0.001) | 2.5 (2.0–3.1, < 0.001) | 2.7 (2.4–3.0, < 0.001) |
TC | – | – | – | – | – |
TCH | 0.6 (0.6–0.7, < 0.001) | 0.7 (0.5–0.9, 0.001) | 0.6 (0.5–0.8, < 0.001) | 0.7 (0.6–0.8, < 0.001) | 0.6 (0.5–0.6, < 0.001) |
CHOP±R | 1.6 (1.5–1.7, < 0.001) | 2.1 (1.9–2.5, < 0.001) | 2.9 (2.6–3.2, < 0.001) | 2.1 (1.9–2.3, < 0.001) | 1.9 (1.8–2.0, < 0.001) |
Age | |||||
65–74 | – | – | – | – | – |
75–84 | 1.2 (1.1–1.3, < 0.001) | 1.0 (0.8–1.1, 0.759) | 1.1 (1.0–1.2, 0.011) | 1.2 (1.1–1.4, < 0.001) | 1.1 (1.1–1.2, < 0.001) |
≥ 85 | 1.4 (1.3–1.6, < 0.001) | 1.1 (1.0–1.3, 0.047) | 1.2 (1.1–1.4, < 0.001) | 1.6 (1.5–1.8, < 0.001) | 1.3 (1.3–1.4, < 0.001) |